XTX Topco Ltd Purchases 51,658 Shares of Arvinas, Inc. (NASDAQ:ARVN)

XTX Topco Ltd boosted its holdings in Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 194.2% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 78,257 shares of the company's stock after acquiring an additional 51,658 shares during the quarter. XTX Topco Ltd owned 0.11% of Arvinas worth $549,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in ARVN. T. Rowe Price Investment Management Inc. bought a new position in Arvinas during the 4th quarter valued at $42,332,000. Boxer Capital Management LLC bought a new position in Arvinas during the 4th quarter valued at $20,294,000. Federated Hermes Inc. boosted its stake in Arvinas by 1,965.0% during the 1st quarter. Federated Hermes Inc. now owns 980,674 shares of the company's stock valued at $6,884,000 after purchasing an additional 933,183 shares in the last quarter. RTW Investments LP boosted its stake in Arvinas by 19.8% during the 4th quarter. RTW Investments LP now owns 3,334,308 shares of the company's stock valued at $63,919,000 after purchasing an additional 551,979 shares in the last quarter. Finally, ArrowMark Colorado Holdings LLC boosted its stake in Arvinas by 42.8% during the 4th quarter. ArrowMark Colorado Holdings LLC now owns 1,776,555 shares of the company's stock valued at $34,057,000 after purchasing an additional 532,105 shares in the last quarter. 95.19% of the stock is currently owned by institutional investors and hedge funds.

Arvinas Stock Performance

Shares of Arvinas stock traded up $0.05 during trading on Friday, reaching $6.29. The company's stock had a trading volume of 2,124,307 shares, compared to its average volume of 2,068,406. The business's fifty day moving average price is $7.52 and its 200-day moving average price is $9.97. The firm has a market cap of $461.81 million, a price-to-earnings ratio of -6.23 and a beta of 2.22. Arvinas, Inc. has a one year low of $5.90 and a one year high of $29.61.

Arvinas (NASDAQ:ARVN - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported ($0.84) earnings per share for the quarter, topping analysts' consensus estimates of ($0.87) by $0.03. Arvinas had a negative return on equity of 12.01% and a negative net margin of 19.47%. The business had revenue of $22.40 million for the quarter, compared to the consensus estimate of $34.42 million. During the same period last year, the business earned ($0.49) earnings per share. The firm's revenue for the quarter was down 70.7% compared to the same quarter last year. Sell-side analysts anticipate that Arvinas, Inc. will post -3.81 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Leerink Partnrs lowered Arvinas from a "strong-buy" rating to a "hold" rating in a research note on Sunday, June 1st. BMO Capital Markets reduced their price objective on Arvinas from $20.00 to $10.00 and set an "outperform" rating for the company in a research note on Monday, May 5th. BTIG Research set a $16.00 price objective on Arvinas and gave the stock a "buy" rating in a research note on Friday, May 2nd. Piper Sandler reissued an "overweight" rating and set a $14.00 price objective (down from $24.00) on shares of Arvinas in a research note on Friday, May 2nd. Finally, Morgan Stanley reduced their price objective on Arvinas from $12.00 to $11.00 and set an "equal weight" rating for the company in a research note on Friday, May 9th. Ten investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $19.76.

Insiders Place Their Bets

In other Arvinas news, CFO Andrew Saik sold 5,700 shares of Arvinas stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $7.61, for a total transaction of $43,377.00. Following the sale, the chief financial officer directly owned 164,401 shares of the company's stock, valued at approximately $1,251,091.61. The trade was a 3.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 4.73% of the company's stock.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.